Skip to content

Oral Administration or Nasal Feeding of Huzhangxiefei Decoction for Treatment in Sepsis Induced Acute Lung Injury

Oral Administration or Nasal Feeding of Huzhangxiefei Decoction for Treatment in Sepsis Induced Acute Lung Injury

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04940676
Enrollment
58
Registered
2021-06-25
Start date
2021-03-10
Completion date
2022-12-31
Last updated
2021-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lung Injury, Sepsis

Keywords

acute lung injury, sepsis, Chinese Traditional Medicine, Chinese Herbal Drugs, acute respiratory distress syndrome

Brief summary

Hypothesis 1A: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will significantly attenuate sepsis-induced systemic organ failure as measured by overall response rate. Hypothesis 1B: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will attenuate sepsis-induced lung injury as assessed by the respiratory rate and oxygenation index. Hypothesis 1C: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will attenuate sepsis-induced lung injury as assessed by chest x-ray scale score, Chinese Medicine scale score. Hypothesis 1D: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

Detailed description

Huzhangxiefei Decoction is a prescription formulated by a professional doctor of traditional Chinese medicine

Interventions

DRUGHuzhangxiefei Decoction

Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days

DRUG10% Huzhangxiefei Decoction

10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must have suspected or proven infection, and be accompanied by at least 1 criterion for sepsis-induced organ dysfunction, and meet all 5 criteria for Acute Respiratory Distress Syndrome (ARDS). Suspected or proven infection: (e.g., thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system). The presence of sepsis associated organ dysfunction: (any of the following thought to be due to infection): Sepsis associated hypotension (systolic blood pressure (SBP) \< 90 mm Hg or an SBP decrease \> 40 mm Hg unexplained by other causes or use of vasopressors for blood pressure support (epinephrine, norepinephrine, dopamine =/\> 5mcg, phenylephrine, vasopressin); Arterial hypoxemia (PaO2/FiO2 \< 300) or supplemental O2 \> 6LPM; Lactate \> upper limits of normal laboratory results; Urine output \< 0.5 ml/kg/hour for \> two hours despite adequate fluid resuscitation; Platelet count \< 100,000 per mcL; Coagulopathy (INR \> 1.5); Bilirubin \> 2 mg/dL; Glasgow Coma Scale \< 11 or a positive CAM ICU score. ARDS characterized by all the following criteria Lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms Bilateral opacities on chest imaging not explained by other pulmonary pathology (e.g. pleural effusions, lung collapse, or nodules) Respiratory failure not explained by heart failure or volume overload Decreased arterial PaO2/FiO2 ratio ≤ 300 mm Hg Minimum PEEP of 5 cmH2O (may be delivered noninvasively with CPAP to diagnose mild ARDS

Exclusion criteria

* inability to obtain consent; * age \< 18 years; * pregnancy or breast feeding; * moribund patient not expected to survive 24 hours; * for patients with chronic liver insufficiency, renal insufficiency, blood system disease, etc., it is impossible to judge that the organ insufficiency occurred after this infection

Design outcomes

Primary

MeasureTime frameDescription
Sequential Organ Failure Assessment (SOFA) Scoreup to 7 daysSOFA is a single score based on patient status of five different biological systems: respiratory, cardiovascular, coagulation, renal, and neurological. Scores range from 0 to 24 with higher scores indicated worse status
C-Reactive Protein at Study Hours 0, 96, 168 When Compared to Placeboup to 168 hoursC-Reactive Protein at Study Hours 0, 96, 168 When Compared to Placebo
Oxygenation Index (FiO2 x Mean Airway Pressure/PaO2) at Study Hour 0, 96, 168 if Still Intubated in Oral Administration or Nasal Feeding of Huzhangxiefei decoction Patient Compared to Placeboup to 168 hoursOxygenation Index (FiO2 x Mean Airway Pressure/PaO2) at Study Hour 0, 96, 168 if Still Intubated in Oral Administration or Nasal Feeding of Huzhangxiefei decoction Patient Compared to Placebo
overall response rateup to 7 daysOverall response rate=(the number of marked response patients+the number of moderate response)/the number of all patients within group Four criteria were established as follows: 1. RR(d1)-RR(d7)≥5 breaths per minute or 12 breaths per minute≤RR(d7)≤20breaths per minute 2. OI(d7)-OI(d1)≥50mmHg 3. \[CXSS(d1)-CXSS(d7)\]/CXSS(d1)≥10% 4. CMSS(d1)-CMSS(d7)≥3 points Marked response: three or four criteria of the above are met Moderate response:two criteria of the above are met No response: none or only one criterion of the above is met RR refers to respiratory rate, breaths per minute OI refers to oxygenation index, mmHg CXSS refers to chest x-ray scale score CMSS refers to Chinese Medicine scale score

Secondary

MeasureTime frameDescription
Procalcitonin at Study Hour 0, 96, 168Up to hour 168Procalcitonin at Study Hour 0, 96, 168
Tissue Factor Pathway Inhibitor at Study Hour 0, 96, 168Up to hour 168Tissue Factor Pathway Inhibitor at Study Hour 0, 96, 168
Oxygenation Score: PressureUp to hour 168Oxygenation as measure by the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2). Scores range from 100 to 300 with lower values indicating more worse outcomes
CoagulationUp to hour 168Coagulation as measured by Platelets per unit of blood. Scores range from less than 20 to more than 150. Lower scores indicate worse outcomes
Ventilator Free Days to Day 28Up to Day 28Ventilator Free Days to Day 28
Cardiovascular FunctionUp to hour 168Cardiovascular function as measured by Mean arterial pressure. Scores less than 70 mmHg indicate worse outcomes.
State of ConsciousnessUp to hour 168State of consciousness as measure by Glasgow Coma Scale which gives a score based on eye, verbal, and motor responses. Scores range from 3 to 15 with lower scores indicating worse outcome
Renal FunctionUp to hour 168Renal function as measured by Creatinine.
Liver FunctionUp to hour 168Liver function as measured by Total Bilirubin
ICU-free Days at Day 28Up to Day 28ICU-free Days at Day 28
All Cause Mortality to Day 28Up to Day 28All Cause Mortality to Day 28
Hospital-free Days at Day 60Up to Day 60Hospital-free Days at Day 60

Countries

China

Contacts

Primary ContactLi Xiang, graduate
1438325179@qq.com86-18555504579

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026